← All stories
Markets 2 sources

Bristol-Myers stock: why AstraZeneca merger is unlikely to happen

Covered by 2 sources · 2 articles

2 outlets - including Yahoo and Invezz - are covering this story. Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According to media reports, the UK healthcare hea…

Covered by

All coverage

Yahoo Finance News Aug 5, 13:11 UTC

AstraZeneca and Bristol Myers Squibb merger talks denied

Bristol-Myers stock: why AstraZeneca merger is unlikely to happen
Invezz Aug 3, 15:20 UTC

Bristol-Myers stock: why AstraZeneca merger is unlikely to happen

Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According to media reports, the UK healthcare hea…